JP2000034233A - Inhibitor of production of nitric oxide - Google Patents
Inhibitor of production of nitric oxideInfo
- Publication number
- JP2000034233A JP2000034233A JP10200543A JP20054398A JP2000034233A JP 2000034233 A JP2000034233 A JP 2000034233A JP 10200543 A JP10200543 A JP 10200543A JP 20054398 A JP20054398 A JP 20054398A JP 2000034233 A JP2000034233 A JP 2000034233A
- Authority
- JP
- Japan
- Prior art keywords
- name
- indonesian
- scientific
- scientific name
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 56
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 239000003112 inhibitor Substances 0.000 title claims abstract description 25
- 239000000284 extract Substances 0.000 claims abstract description 85
- 241000196324 Embryophyta Species 0.000 claims abstract description 44
- RAPBNVDSDCTNRC-UHFFFAOYSA-N Chlorobenzilate Chemical compound C=1C=C(Cl)C=CC=1C(O)(C(=O)OCC)C1=CC=C(Cl)C=C1 RAPBNVDSDCTNRC-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 240000005369 Alstonia scholaris Species 0.000 claims abstract description 10
- 244000118350 Andrographis paniculata Species 0.000 claims abstract description 10
- 241000283162 Inia geoffrensis Species 0.000 claims abstract description 10
- 244000145321 Acmella oleracea Species 0.000 claims abstract description 9
- 244000226475 Alyxia reinwardti Species 0.000 claims abstract description 9
- 244000306301 Caesalpinia sappan Species 0.000 claims abstract description 9
- 235000015162 Caesalpinia sappan Nutrition 0.000 claims abstract description 9
- 240000001723 Entada phaseoloides Species 0.000 claims abstract description 9
- 241000616594 Equisetum ramosissimum subsp. debile Species 0.000 claims abstract description 9
- 240000004980 Rheum officinale Species 0.000 claims abstract description 9
- 235000008081 Rheum officinale Nutrition 0.000 claims abstract description 9
- 244000248051 Schima wallichii Species 0.000 claims abstract description 9
- 244000079492 Sindora javanica Species 0.000 claims abstract description 9
- 244000111306 Torreya nucifera Species 0.000 claims abstract description 9
- 235000006732 Torreya nucifera Nutrition 0.000 claims abstract description 9
- 241000006302 Usnea Species 0.000 claims abstract description 9
- 240000004934 Vitex trifolia Species 0.000 claims abstract description 9
- 244000082781 white kyllinga Species 0.000 claims abstract description 9
- 244000226021 Anacardium occidentale Species 0.000 claims abstract description 8
- 235000001274 Anacardium occidentale Nutrition 0.000 claims abstract description 8
- 241000722826 Ardisia Species 0.000 claims abstract description 7
- 244000086950 Justicia picta Species 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 67
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 239000001569 carbon dioxide Substances 0.000 claims description 10
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 9
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 241000530025 Gymnopetalum Species 0.000 claims description 8
- 244000157344 Kyllinga brevifolia Species 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 7
- 241001290529 Kyllinga clade Species 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 22
- 210000002540 macrophage Anatomy 0.000 description 18
- 239000002158 endotoxin Substances 0.000 description 13
- 238000000605 extraction Methods 0.000 description 13
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 10
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 10
- 238000003756 stirring Methods 0.000 description 9
- -1 for example Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 235000013305 food Nutrition 0.000 description 7
- 229960003753 nitric oxide Drugs 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 3
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 3
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940112822 chewing gum Drugs 0.000 description 3
- 235000015218 chewing gum Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102100032381 Alpha-hemoglobin-stabilizing protein Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000797984 Homo sapiens Alpha-hemoglobin-stabilizing protein Proteins 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000013353 coffee beverage Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000021552 granulated sugar Nutrition 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 239000001341 hydroxy propyl starch Substances 0.000 description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 230000002883 vasorelaxation effect Effects 0.000 description 2
- YGVMJVSXFJRHGQ-WCCKRBBISA-N (2S)-2-amino-5-[[amino(hydrazinyl)methylidene]amino]pentanoic acid hydrochloride Chemical compound Cl.NN\C(N)=N\CCC[C@H](N)C(O)=O YGVMJVSXFJRHGQ-WCCKRBBISA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- QQZOPKMRPOGIEB-UHFFFAOYSA-N 2-Oxohexane Chemical compound CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 102100032566 Carbonic anhydrase-related protein 10 Human genes 0.000 description 1
- 240000004385 Centaurea cyanus Species 0.000 description 1
- 235000005940 Centaurea cyanus Nutrition 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000867836 Homo sapiens Carbonic anhydrase-related protein 10 Proteins 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- UYZFAUAYFLEHRC-LURJTMIESA-N L-NIO Chemical compound CC(N)=NCCC[C@H](N)C(O)=O UYZFAUAYFLEHRC-LURJTMIESA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- UYZFAUAYFLEHRC-UHFFFAOYSA-N NG-iminoethyl-L-ornithine Natural products CC(N)=NCCCC(N)C(O)=O UYZFAUAYFLEHRC-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 1
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 101000872823 Xenopus laevis Probable histone deacetylase 1-A Proteins 0.000 description 1
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 description 1
- DUHSSNQZRMKHLD-UHFFFAOYSA-N [Ca].[Ca].[Ca].P(O)(O)(O)=O Chemical compound [Ca].[Ca].[Ca].P(O)(O)(O)=O DUHSSNQZRMKHLD-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- LFVVNPBBFUSSHL-UHFFFAOYSA-N alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 description 1
- 229950010221 alexidine Drugs 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000000066 endothelium dependent relaxing factor Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 108010000165 exo-1,3-alpha-glucanase Proteins 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012623 in vivo measurement Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 235000021539 instant coffee Nutrition 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 230000020796 long term synaptic depression Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000001129 nonadrenergic effect Effects 0.000 description 1
- 230000002536 noncholinergic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical group 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 229960000414 sodium fluoride Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
- 229960002799 stannous fluoride Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、特定の植物またはその
抽出物を有効成分とする一酸化窒素産生抑制剤に関す
る。The present invention relates to a nitric oxide production inhibitor comprising a specific plant or an extract thereof as an active ingredient.
【0002】[0002]
【従来の技術】1980年代前半、生体内における窒素
酸化物の研究過程で、一酸化窒素( 以下、NOと略す場
合がある)が生体内で産生していることが初めて見出さ
れた。その発見をきっかけに、NOは多くの研究者の注
目を集め、1987年には、NOが血管内皮細胞由来弛
緩因子の本体であるとの報告がなされた。そして、現在
では、循環、免疫、神経系等広い分野で、NOの生理機
能や病態との関連が明らかにされている。そのうち、例
えば、体内で常時産生されているNOは、循環動態の恒
常性を維持する重要な役割を担っていることが解明され
ている。また一方、敗血症においては、エンドトキシン
により活性化されたサイトカインの働きにより、大量の
NOが産生され、これが内皮細胞障害、心筋収縮力低下
等のエンドトキシンショック状態を引き起こすといわれ
ている。BACKGROUND OF THE INVENTION In the early 1980's, during the study of nitrogen oxides in vivo, it was first discovered that nitric oxide (hereinafter sometimes abbreviated as NO) was produced in vivo. Following that discovery, NO attracted the attention of many researchers, and in 1987, it was reported that NO was the main body of vascular endothelial cell-derived relaxing factor. At present, the relationship between NO physiological functions and disease states has been elucidated in a wide range of fields such as circulation, immunity, and nervous system. Among them, for example, it has been elucidated that NO constantly produced in the body plays an important role in maintaining hemodynamic homeostasis. On the other hand, in sepsis, it is said that a large amount of NO is produced by the action of cytokines activated by endotoxin, and this causes an endotoxin shock state such as endothelial cell damage and reduced myocardial contractility.
【0003】従来より、血管弛緩および血小板凝集抑制
作用を有する内因性生理活性物質としてプロスタサイク
リンが知られていたが、それ以外の新たな血管弛緩物質
が1980年にFurchgott らにより内皮細胞由来血管拡張因
子(Endothelium Derived Relaxing Factor,EDRF)として
発見され、これがNOと同一であることが1987年にMonc
ada らおよびIgnarro らのグループにより証明された(I
gnarro,L.J. : Endothelium-derived nitric oxide : a
ctions and properties. FASEB J. 3, 31-36,1989., Kn
owles,R.G.and Moncada,S.:Nitric oxide asa signal i
n blood vessels.Trends Biochem.Sci.17, 399-402,199
2., Moncada,S., Palmer,R.M.J. and Higgs,E.A. : Nit
ric oxide: physiology, pathophysiology and pharmac
ology.Pharmacolog. Rev. 43, 109-142, 1991.) 。Conventionally, prostacyclin has been known as an endogenous physiologically active substance having an inhibitory effect on vasorelaxation and platelet aggregation, but another new vasorelaxant was discovered in 1980 by Furchgott et al. Was discovered as a factor (Endothelium Derived Relaxing Factor, EDRF), and in 1987 Monc was found to be identical to NO.
ada et al. and Ignarro et al.
gnarro, LJ: Endothelium-derived nitric oxide: a
ctions and properties.FASEB J. 3, 31-36,1989., Kn
owles, RGand Moncada, S.: Nitric oxide asa signal i
n blood vessels. Trends Biochem. Sci. 17, 399-402,199
2., Moncada, S., Palmer, RMJ and Higgs, EA: Nit
ric oxide: physiology, pathophysiology and pharmac
ology.Pharmacolog. Rev. 43, 109-142, 1991.).
【0004】それ以来、循環器系以外においても、神経
系さらに免疫系など生体内の多くの生理機能における情
報伝達物質としてのNOの役割が次々に明かにされてい
る。すなわち、神経系では、神経伝達物質として働き、
シナプス可塑性( 小脳長期抑圧現象や海馬長期増強現
象) の成立に関与しており( 渋木克栄: NOと神経系の
可塑性−小脳長期抑圧の調節. 実験医学11,2451-2456,1
993.) 、さらに、免疫系では腫瘍細胞や病原体に対する
生体防御機構において、エフェクター細胞として働いて
いるマクロファージから産生されるNOの重要性が指摘
されている( 滝龍雄、中野昌康: マクロファージにおけ
るアルギニンおよびその代謝産物による抗菌抗腫瘍作
用. 医学のあゆみ156,194-197,1991.)。血管拡張作用に
限っても、EDRFとして血管内膜側から作用するだけでな
く、非アドレナリン・非コリン作動性の血管拡張神経の
伝達物質として外膜側からも作用することが証明されて
おり、NOが複雑なメカニズムにより種々の生理機能の
調節を行っていることが指摘されている。[0004] Since then, the role of NO as a signal transmitting substance in many physiological functions in the living body, such as the nervous system and the immune system, other than the circulatory system, has been revealed one after another. That is, in the nervous system, it acts as a neurotransmitter,
It is involved in the establishment of synaptic plasticity (long-term cerebellar depression and long-term hippocampal phenomena) (Katsuei Shibuki: NO and plasticity of the nervous system-regulation of long-term depression of the cerebellum. Experimental Medicine 11,2451-2456,1
993.) Furthermore, in the immune system, the importance of NO produced from macrophages acting as effector cells has been pointed out in the host defense mechanism against tumor cells and pathogens (Takio Taki, Masayasu Nakano: Arginine and macrophage in macrophages) Antibacterial and antitumor effects of its metabolites. History of medicine 156,194-197,1991.). Even if it is limited to vasodilator action, it has been proved that it acts not only from the intima side as EDRF but also acts from the outer membrane side as a non-adrenergic / non-cholinergic vasodilator neurotransmitter It has been pointed out that NO regulates various physiological functions by a complicated mechanism.
【0005】このように生体内で産生されることが明ら
かになったNOは、L−アルギニンを基質として一酸化
窒素合成酵素(NOS)により生成される。NOSには
少なくとも非誘導型(血管内皮型および神経型)および
誘導型のアイソザイムが存在する。血管内皮型NOS
は、主に血管内皮細胞に存在し、細胞内カルシウム濃度
により活性が制御されている。神経型NOSは、中枢神
経細胞、末梢神経細胞、または膵島β細胞、消化管神
経、副腎髄質、腎臓緻密斑等に存在し、血管内皮型NO
Sと同様に細胞内カルシウム濃度により活性が制御され
ている。[0005] NO, which has been found to be produced in vivo as described above, is produced by nitric oxide synthase (NOS) using L-arginine as a substrate. NOS has at least non-inducible (vascular endothelial and neural) and inducible isozymes. Endothelial NOS
Is mainly present in vascular endothelial cells, and its activity is controlled by the intracellular calcium concentration. Neuronal NOS is present in central nerve cells, peripheral nerve cells, or pancreatic islet β-cells, gastrointestinal nerves, adrenal medulla, renal compact plaques, etc.
Similar to S, the activity is controlled by the intracellular calcium concentration.
【0006】血管内皮型NOSおよび神経型NOS(co
nstitutive NOS、c-NOS と省略される)は細胞内に恒常
的に存在し、生理的変化による酵素量の変化はほとんど
見られない。誘導型NOS(inducible NOS 、i-NOS と
省略される)は、肝実質細胞、好中球、マクロファー
ジ、平滑筋、線維芽細胞、腎メサンギウム細胞、消化管
上皮、膵島β細胞、血管平滑筋細胞またはグリア細胞等
に存在する。これは通常細胞内で認められず、エンドト
キシンや各種サイトカイン等による刺激により誘導され
る。[0006] Endothelial NOS and neural NOS (co
nstitutive NOS, abbreviated as c-NOS) is constantly present in cells, and there is almost no change in the amount of enzymes due to physiological changes. Inducible NOS (abbreviated as inducible NOS, i-NOS) includes hepatic parenchymal cells, neutrophils, macrophages, smooth muscle, fibroblasts, renal mesangial cells, gastrointestinal epithelium, pancreatic islet β cells, vascular smooth muscle cells Or it exists in glial cells and the like. This is not usually observed in cells, but is induced by stimulation with endotoxin, various cytokines, and the like.
【0007】NOSにより生成されるNOの作用は多彩
であり、例えば、血管弛緩作用、血小板凝集抑制作用、
粘着抑制、白血球粘着・遊走抑制、交感神経活動抑制、
エンドトキシンショック、エンドトキシン・サイトカイ
ンによる低血圧による障害、神経細胞間の情報伝達物質
としての作用、虚血性脳細胞障害、抗腫瘍、殺菌作用、
自己免疫疾患、インスリン依存性糖尿病、関節炎、移植
後組織障害、拒絶反応等が挙げられる。[0007] The action of NO produced by NOS is diverse and includes, for example, vasorelaxant action, platelet aggregation inhibitory action,
Adhesion suppression, leukocyte adhesion / migration suppression, sympathetic nerve activity suppression,
Endotoxin shock, damage due to hypotension due to endotoxin / cytokine, action as a signal transmitter between nerve cells, ischemic brain cell damage, antitumor, bactericidal action,
Autoimmune diseases, insulin-dependent diabetes mellitus, arthritis, tissue damage after transplantation, rejection and the like.
【0008】生体内でのNOの生理活性を解析する上
で、NO合成酵素阻害剤は有用であり、またショックや
虚血性疾患等の治療薬として用いられる可能性があるこ
とより、近年種々のNOS阻害剤の開発が現在進められ
ている。例えば、基質競合剤としてアルギニン類似体が
あり、Nω−モノメチル−L−アルギニン(L−NMM
A)、Nω−ニトロ−L−アルギニン(L−NNA)、
Nω−アミノ−L−アルギニン(L−NAA)、Nω−
イミノエチル−オルニチン(L−NIO)等がそれに当
たる。[0008] In analyzing the physiological activity of NO in vivo, NO synthase inhibitors are useful and may be used as therapeutic agents for shock and ischemic diseases. Development of NOS inhibitors is currently underway. For example, there is an arginine analog as a substrate competitor, and Nω-monomethyl-L-arginine (L-NMM
A), Nω-nitro-L-arginine (L-NNA),
Nω-amino-L-arginine (L-NAA), Nω-
Iminoethyl-ornithine (L-NIO) and the like correspond thereto.
【0009】しかしながら、上記代表例を含む従来公知
のNOS阻害剤は、iNOSだけでなく、cNOSをも
阻害してしまうものが殆どであり、之等の治療薬として
の利用によれば、恒常的な循環動態の調節までもが抑制
されてしまい、血圧上昇、臓器血流減少等の副作用を回
避することはできない。更に、之等の利用時には、中枢
神経系への影響やインポテンツ等の問題も懸念される。
以上のように、従来知られているNOS阻害剤は、医薬
品として評価できるものではなく、これらに代わって、
iNOSを選択的に阻害することのできるNO産生抑制
作用を有する薬剤の開発が求められていた。[0009] However, most of the known NOS inhibitors including the above representative examples inhibit not only iNOS but also cNOS. Even the regulation of circulatory dynamics is suppressed, and it is not possible to avoid side effects such as an increase in blood pressure and a decrease in organ blood flow. In addition, there is a concern that the use of these methods may affect the central nervous system and impotence.
As described above, conventionally known NOS inhibitors cannot be evaluated as pharmaceuticals.
There has been a demand for the development of a drug having an NO production inhibitory action capable of selectively inhibiting iNOS.
【0010】[0010]
【課題を解決するための手段】本発明者らは、iNOS
を選択的に阻害することのできるNO産生抑制作用を有
する薬剤を見出すべく鋭意検討を行った結果、特定のイ
ンドネシアの民間伝承薬およびその抽出物にNO産生抑
制作用があることを見出し本発明を完成した。Means for Solving the Problems The present inventors have developed iNOS.
As a result of diligent studies to find a drug having an NO production inhibitory action capable of selectively inhibiting NR, it was found that a specific Indonesian folklore drug and its extract have an NO production inhibitory action, completed.
【0011】すなわち本発明は、 学名: Andrographis paniculata インドネシア名(Sambi boto) 学名: Caesalpinia sappan インドネシア名(Kaya secang) 学名: Schima wallichii インドネシア名(Buah cangkok) 学名: Alstonia scholaris インドネシア名(Babakan pule) 学名: Graptophyllum pictum インドネシア名(Daum wungu) 学名: Usnea spp. インドネシア名(Akar angin) 学名: Rheum officinale インドネシア名(Klembak) 学名: Sindora javanica インドネシア名(Saparantu) 学名: Vitex trifolia インドネシア名(Legundi) 学名: Anacardium occidentale インドネシア名(Daun jambu mete) 学名: Gymnopetalum leucosticum インドネシア名(Duri kemarung) 学名: Equisetum debile インドネシア名(Greges otot) 学名: Kyllinga monocephala インドネシア名(Akar teki) 学名: Kyllinga brevifolia インドネシア名(Akar teki) 学名: Ardisia fuliginosa インドネシア名(Ajag) 学名: Entada phaseoloides インドネシア名(Tariyu) 及び 学名: Alyxia reinwardti インドネシア名(Kayu polo sari) からなる群より選ばれる少なくとも一種以上の植物体そ
のもの、又は植物の溶媒抽出液あるいは炭酸ガスを使用
する超臨界抽出法により抽出された抽出物を有効成分と
して含有することを特徴とするNO産生抑制剤である。
本発明はまた、 学名: Andrographis paniculata インドネシア名(Sambi boto)の全草 学名: Caesalpinia sappan インドネシア名(Kaya secang) の木部 学名: Schima wallichii インドネシア名(Buah cangkok)実 学名: Alstonia scholaris インドネシア名(Babakan pule)の樹皮 学名: Graptophyllum pictum インドネシア名(Daum wungu)の全草 学名: Usnea spp. インドネシア名(Akar angin)の全草 学名: Rheum officinale インドネシア名(Klembak) の根 学名: Sindora javanica インドネシア名(Saparantu) の実 学名: Vitex trifolia インドネシア名(Legundi) の葉 学名: Anacardium occidentale インドネシア名(Daun jambu mete) の葉 学名: Gymnopetalum leucosticum インドネシア名(Duri kemarung) の棘 学名: Equisetum debile インドネシア名(Greges otot) の茎 学名: Kyllinga monocephala インドネシア名(Akar teki) の全草 学名: Kyllinga brevifolia インドネシア名(Akar teki) の全草 学名: Ardisia fuliginosa インドネシア名(Ajag)の全草 学名: Entada phaseoloides インドネシア名(Tariyu)の茎・葉 及び 学名: Alyxia reinwardti インドネシア名(Kayu polo sari)の茎 からなる群より選ばれる少なくとも一種以上の植物体そ
のもの、又は植物の溶媒抽出液あるいは炭酸ガスを使用
する超臨界抽出法により抽出された抽出物を有効成分と
して含有することを特徴とする一酸化窒素産生抑制剤で
ある。本発明はさらに、上記溶媒がクロロホルム、メタ
ノール、エタノール、プロピレングリコール及び1, 3
−ブチレングリコールからなる群から選ばれる少なくと
も1種であることを特徴とするNO産生抑制剤である。That is, the present invention provides a scientific name: Andrographis paniculata Indonesian name (Sambi boto) Scientific name: Caesalpinia sappan Indonesian name (Kaya secang) Scientific name: Schima wallichii Indonesian name (Buah cangkok) Scientific name: Alstonia scholaris Indonesian name (Babakan pule) Graptophyllum pictum Indonesian name (Daum wungu) Scientific name: Usnea spp. Indonesian name (Akar angin) Scientific name: Rheum officinale Indonesian name (Klembak) Scientific name: Sindora javanica Indonesian name (Saparantu) Scientific name: Vitex trifolia Indonesian name (Legundi) occidental identium Anacard Indonesian name (Daun jambu mete) Scientific name: Gymnopetalum leucosticum Indonesian name (Duri kemarung) Scientific name: Equisetum debile Indonesian name (Greges otot) Scientific name: Kyllinga monocephala Indonesian name (Akar teki) Scientific name: Kyllinga brevifolia Indonesian name (Akar t) fuliginosa Indonesian name (Ajag) Scientific name: Entada phaseoloides Indonesian name (Tariyu) and scientific name: Alyxia reinwardti At least one plant selected from the group consisting of Indonesian name (Kayu polo sari), or by a supercritical extraction method using a plant solvent extract or carbon dioxide gas An NO production inhibitor characterized by containing an extracted extract as an active ingredient.
The present invention also relates to the whole name of Andrographis paniculata Indonesian name (Sambi boto) Scientific name: Caesalpinia sappan Indonesian name (Kaya secang) Wood part Scientific name: Schima wallichii Indonesian name (Buah cangkok) Real scientific name: Alstonia scholaris Indonesian name (Babakan pule) bark Scientific name: Graptophyllum pictum Indonesian name (Daum wungu) whole plant Scientific name: Usnea spp. Indonesian name (Akar angin) whole plant Scientific name: Rheum officinale Indonesian name (Klembak) Root Scientific name: Sindora javanica Indonesian name (Saparantu) Scientific name: Vitex trifolia Indonesian name (Legundi) Leaf Scientific name: Anacardium occidentale Indonesian name (Daun jambu mete) Leaf Scientific name: Gymnopetalum leucosticum Indonesian name (Duri kemarung) Thorn Scientific name: Equisetum debile Indonesian name (Greges otot) Stalk Scientific name: Kyllinga monocephala Whole plant of Indonesian name (Akar teki) Scientific name: Kyllinga brevifolia Indonesian name (A kar teki) whole plant Scientific name: Ardisia fuliginosa Indonesian name (Ajag) whole plant Scientific name: Entada phaseoloides Indonesian name (Tariyu) stem / leaf and scientific name: Alyxia reinwardti Indonesian name (Kayu polo sari) stem A nitric oxide production inhibitor characterized by containing at least one or more plants themselves, or an extract extracted by a supercritical extraction method using a solvent extract of plants or carbon dioxide as an active ingredient. . The invention further provides that the solvent is chloroform, methanol, ethanol, propylene glycol and 1,3
A NO production inhibitor, which is at least one member selected from the group consisting of butylene glycol.
【0012】本発明のNO産生抑制に有効であることが
示された上述のインドネシア由来の植物は、古くからの
民間伝承薬として言い伝えられており、ジャムウ( 中国
で言う漢方の様なもの) の構成成分として用いられてい
る。しかし、これらの植物およびその抽出液、また、そ
れらを構成成分とするジャムウが、NO産生抑制作用を
有することは全く知られていなかったことである。The above-mentioned plant derived from Indonesia, which has been shown to be effective in suppressing NO production according to the present invention, has been reported as an ancient folklore, and is derived from Jamu (like Chinese herbal medicine in China). Used as a constituent. However, it has never been known that these plants, their extracts, and jams containing them as components have NO production inhibitory action.
【0013】[0013]
【発明の実施の形態】以下に本発明を詳細に説明する。原材料 本発明に好ましく用いられる 学名: Andrographis paniculata インドネシア名(Sambi boto)の全草 学名: Caesalpinia sappan インドネシア名(Kaya secang) の木部 学名: Schima wallichii インドネシア名(Buah cangkok)実 学名: Alstonia scholaris インドネシア名(Babakan pule)の樹皮 学名: Graptophyllum pictum インドネシア名(Daum wungu)の全草 学名: Usnea spp. インドネシア名(Akar angin)の全草 学名: Rheum officinale インドネシア名(Klembak) の根 学名: Sindora javanica インドネシア名(Saparantu) の実 学名: Vitex trifolia インドネシア名(Legundi) の葉 学名: Anacardium occidentale インドネシア名(Daun jambu mete) の葉 学名: Gymnopetalum leucosticum インドネシア名(Duri kemarung) の棘 学名: Equisetum debile インドネシア名(Greges otot) の茎 学名: Kyllinga monocephala インドネシア名(Akar teki) の全草 学名: Kyllinga brevifolia インドネシア名(Akar teki) の全草 学名: Ardisia fuliginosa インドネシア名(Ajag)の全草 学名: Entada phaseoloides インドネシア名(Tariyu) の茎・葉 学名: Alyxia reinwardti インドネシア名(Kayu polo sari) の乾燥したものは、インドネシアの市場をはじめ他国の
市場でも入手できる。DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will be described below in detail. Ingredients preferably used in the present invention Scientific name: Andrographis paniculata Indonesian name (Sambi boto) Whole plant Scientific name: Caesalpinia sappan Indonesian name (Kaya secang) Kibe Scientific name: Schima wallichii Indonesian name (Buah cangkok) Real scientific name: Alstonia scholaris Indonesian name Bark of (Babakan pule) Scientific name: Graptophyllum pictum Whole plant of Indonesian name (Daum wungu) Scientific name: Usnea spp. Whole plant of Indonesian name (Akar angin) Scientific name: Rheum officinale Root of Indonesian name (Klembak) Scientific name: Sindora javanica Indonesian name (Saparantu) Scientific name: Vitex trifolia Indonesian name (Legundi) Leaf Scientific name: Anacardium occidentale Indonesian name (Daun jambu mete) Leaf Scientific name: Gymnopetalum leucosticum Indonesian name (Duri kemarung) Thorn Scientific name: Equisetum debile Indonesian name (Greges) ) Stem Scientific name: Kyllinga monocephala Indonesian name (Akar teki) Scientific name: Kyllinga brevifo lia Whole plant of Indonesian name (Akar teki) Scientific name: Ardisia fuliginosa Whole plant of Indonesian name (Ajag) Scientific name: Entada phaseoloides Stem and leaf of Indonesian name (Tariyu) Scientific name: Alyxia reinwardti Dry name of Indonesian name (Kayu polo sari) Is also available in other markets, including the Indonesian market.
【0014】有効成分の抽出 植物をそのまま切裁せずに用いても良いが、抽出操作の
前に切裁した植物を用いたほうが抽出時間を短縮できる
点でより好ましい。上記原材料からの有効成分の抽出方
法として公知の方法が採用でき、例えば炭酸ガスを使用
する超臨界抽出法や溶媒による抽出法が挙げられる。溶
媒による抽出法としては、例えば、原材料に溶媒を添加
して溶媒の還流温度下で加熱処理する方法が挙げられ
る。この加熱処理は一般に80℃以下の温度で実施する
ことが好ましく、公知の抽出装置を用いて還流下1〜6
時間加熱処理することによって抽出液を得ることができ
る。また、溶媒中に前記原材料の乾燥粉末を温浸するこ
とによって抽出液を得ることもできる。超臨界流体は、
その溶解力を圧力、温度により容易にしかも広範囲に渡
って連続的に制御できるため、この性質を利用した超臨
界抽出法は、新たな分離法として期待されている。特に
超臨界二酸化炭素(SC−CO2 )は、臨界点(臨界温
度304.2K,臨界圧力72.8atm)が比較的低
いため、熱的に不安定な物質にも適用可能である。超臨
界抽出法と溶媒による抽出法を組み合わせて使用しても
よい。これらの抽出操作は、1回目の抽出操作を終えた
原料残留物で繰り返して実施することができる。抽出に
使用する溶媒の量は、原材料100重量部当たり100
〜10, 000重量部が適当であり、さらに好ましくは
300〜5, 000重量部である。Although the extracted plant of the active ingredient may be used without being cut as it is, it is more preferable to use the cut plant before the extraction operation in that the extraction time can be shortened. As a method for extracting the active ingredient from the raw materials, a known method can be employed, and examples thereof include a supercritical extraction method using carbon dioxide gas and an extraction method using a solvent. Examples of the extraction method using a solvent include a method in which a solvent is added to a raw material and heat treatment is performed at a reflux temperature of the solvent. In general, this heat treatment is preferably performed at a temperature of 80 ° C. or lower, and is performed under reflux using a known extraction device.
An extract can be obtained by heating for a time. Alternatively, an extract can be obtained by digesting the dry powder of the raw material in a solvent. Supercritical fluid is
Since its dissolving power can be easily and continuously controlled by pressure and temperature over a wide range, the supercritical extraction method utilizing this property is expected as a new separation method. In particular, supercritical carbon dioxide (SC-CO 2 ) has a relatively low critical point (critical temperature 304.2 K, critical pressure 72.8 atm), and thus can be applied to thermally unstable substances. The supercritical extraction method and the extraction method using a solvent may be used in combination. These extraction operations can be repeatedly performed on the raw material residue after the first extraction operation. The amount of solvent used for extraction is 100 per 100 parts by weight of raw material.
The suitable amount is from 10 to 10,000 parts by weight, more preferably from 300 to 5,000 parts by weight.
【0015】本発明において使用できる抽出溶媒として
は、水、低級アルコールであるメタノール、エタノー
ル、プロピルアルコール、イソプロピルアルコール、ブ
タノール、イソブタノール等、あるいはプロピレングリ
コール、1, 3ブチレングリコール等の多価アルコー
ル、アセトン、ジオキサン、メチルエチルケトン、アセ
トニトリル、酢酸エチル、ブチルメチルケトン、ジエチ
ルエーテル、ジクロロメタン、キシレン、トリクロロエ
チレン、四塩化炭素、ベンゼン、クロロホルム及びトル
エン等が挙げられる。特に、クロロホルム、メタノー
ル、エタノール、プロピレングリコール、1, 3−ブチ
レングリコールが好ましい。上記の溶媒を単独で使用し
ても、2種以上を混合して使用してもよく、水と有機溶
媒を併用してもよい。上記の低級アルコール及び多価ア
ルコールを含水アルコールとして使用する場合は、水分
含量50%以下が好ましい。このようにして得られた抽
出液を減圧濃縮して、次いで乾燥することによって抽出
物を粉末として得ることができる。また、使用する溶媒
によっては抽出液をそのままNO産生抑制剤の有効成分
として使用することが可能であり、例えばエタノール、
プロピレングリコール、1, 3−ブチレングリコール等
による抽出液はそのまま溶媒を除去せずに使用してもよ
い。Examples of the extraction solvent usable in the present invention include water, lower alcohols such as methanol, ethanol, propyl alcohol, isopropyl alcohol, butanol and isobutanol, and polyhydric alcohols such as propylene glycol and 1,3-butylene glycol. Acetone, dioxane, methyl ethyl ketone, acetonitrile, ethyl acetate, butyl methyl ketone, diethyl ether, dichloromethane, xylene, trichloroethylene, carbon tetrachloride, benzene, chloroform, toluene and the like can be mentioned. Particularly, chloroform, methanol, ethanol, propylene glycol, and 1,3-butylene glycol are preferred. The above solvents may be used alone, or two or more kinds may be used as a mixture, or water and an organic solvent may be used in combination. When the lower alcohol and the polyhydric alcohol are used as hydroalcohols, the water content is preferably 50% or less. The extract thus obtained is concentrated under reduced pressure, and then dried to obtain the extract as a powder. Also, depending on the solvent used, it is possible to use the extract as it is as an active ingredient of the NO production inhibitor, for example, ethanol,
An extract with propylene glycol, 1,3-butylene glycol or the like may be used without removing the solvent.
【0016】超臨界抽出法は、食品、化学、医薬、化粧
品工業など幅広い分野で注目を集めている抽出技術であ
る。特に、抽剤として二酸化炭素を用いた場合は、その
臨界点(75kg/cm2 、31℃)が比較的低く安全
性が高いため、熱に対して不安定な成分や揮発性の高い
成分等を効率よく抽出分離することができる。原料から
目的の成分を抽出するためには、二酸化炭素の圧力・温
度を臨界点以上に設定することにより達せられる。一般
的には、同じ温度であれば圧力が高いほど超臨界二酸化
炭素の溶解力は増す。本発明における超臨界二酸化炭素
抽出は、自体公知の方法で行うことができる。例えば、
超臨界抽出装置を用い、高圧セル部の温度33〜40
℃、好ましくは35℃、圧力75〜300atm 、好まし
くは150atm とし、二酸化炭素の流量0. 5〜5. 0
dm3 /分、好ましくは4. 0dm3 /分の条件下で行うこ
とができる。これにより、NO産生抑制剤を含む抽出物
が効率よく回収できる。The supercritical extraction method is an extraction technique that has attracted attention in a wide range of fields such as the food, chemical, pharmaceutical, and cosmetic industries. In particular, when carbon dioxide is used as an extractant, the critical point (75 kg / cm 2 , 31 ° C.) is relatively low and the safety is high, so that components unstable to heat and highly volatile components are used. Can be efficiently extracted and separated. Extraction of a target component from a raw material can be achieved by setting the pressure and temperature of carbon dioxide at or above a critical point. Generally, at the same temperature, the higher the pressure, the higher the dissolving power of supercritical carbon dioxide. The supercritical carbon dioxide extraction in the present invention can be performed by a method known per se. For example,
Using a supercritical extraction device, the temperature of the high pressure cell section is 33-40.
C., preferably 35.degree. C., a pressure of 75 to 300 atm, preferably 150 atm, and a flow rate of carbon dioxide of 0.5 to 5.0.
dm 3 / min, preferably at a condition of 4. 0dm 3 / min. Thereby, the extract containing the NO production inhibitor can be efficiently collected.
【0017】本発明のNO産生抑制剤に、有効成分であ
る上記原材料の抽出物の他に、該抽出物に有害でなく且
つ該NO産生抑制剤を利用する製品に不適当でない限
り、適宜添加剤を常法に従って配合することが可能であ
り、また、グリチルリチン酸、グリチルリチン酸ジカリ
ウム、塩化リゾチーム、溶菌酵素、ムタナーゼ、クロル
ヘキシジン、ソルビン酸、アレキシジン、ヒノキチオー
ル、セチルピリジニウムクロライド、アルキルグリシ
ン、アルキルジアミノエチルグリシン塩、アラントイ
ン、ε−アミノカプロン酸、アズレン、ビタミンE及び
その誘導体、モノフルオロリン酸ナトリウム、フッ化ナ
トリウム、フッ化第1錫、水溶性第1若しくは第2リン
酸塩、第4級アンモニウム化合物、塩化ナトリウム等の
有効成分を配合することもできる。In addition to the extract of the above-mentioned raw materials, which is an active ingredient, the NO production inhibitor of the present invention may be appropriately added to the extract unless it is not harmful to the extract and is not suitable for a product utilizing the NO production inhibitor. It is possible to mix the agent according to a conventional method, and glycyrrhizic acid, dipotassium glycyrrhizinate, lysozyme chloride, lytic enzyme, mutanase, chlorhexidine, sorbic acid, alexidine, hinokitiol, cetylpyridinium chloride, alkyl glycine, alkyl diaminoethyl glycine Salt, allantoin, ε-aminocaproic acid, azulene, vitamin E and derivatives thereof, sodium monofluorophosphate, sodium fluoride, stannous fluoride, water-soluble primary or secondary phosphate, quaternary ammonium compound, Incorporation of active ingredients such as sodium chloride It can be.
【0018】製品への応用 本発明のNO産生抑制剤は、好ましくは、 学名: Andrographis paniculata インドネシア名(Sambi boto)の全草 学名: Caesalpinia sappan インドネシア名(Kaya secang) の木部 学名: Schima wallichii インドネシア名(Buah cangkok)実 学名: Alstonia scholaris インドネシア名(Babakan pule)の樹皮 学名: Graptophyllum pictum インドネシア名(Daum wungu)の全草 学名: Usnea spp. インドネシア名(Akar angin)の全草 学名: Rheum officinale インドネシア名(Klembak) の根 学名: Sindora javanica インドネシア名(Saparantu) の実 学名: Vitex trifolia インドネシア名(Legundi) の葉 学名: Anacardium occidentale インドネシア名(Daun jambu mete) の葉 学名: Gymnopetalum leucosticum インドネシア名(Duri kemarung) の棘 学名: Equisetum debile インドネシア名(Greges otot) の茎 学名: Kyllinga monocephala インドネシア名(Akar teki) の全草 学名: Kyllinga brevifolia インドネシア名(Akar teki) の全草 学名: Ardisia fuliginosa インドネシア名(Ajag)の全草 学名: Entada phaseoloides インドネシア名(Tariyu) の茎・葉 学名: Alyxia reinwardti インドネシア名(Kayu polo sari)の茎 より選ばれる1 種または2 種以上のインドネシアの民間
伝承薬をそのまま、またはその抽出物を有効成分とし、
これを公知の医薬用担体と組み合せて製剤化すればよ
い。 Application to Products The NO production inhibitor of the present invention is preferably a scientific name: whole plant of Andrographis paniculata Indonesian name (Sambi boto) Scientific name: Caesalpinia sappan Indonesian name (Kaya secang) Kobe Scientific name: Schima wallichii Indonesia Name (Buah cangkok) Practical name: Alstonia scholaris Bark of Indonesian name (Babakan pule) Scientific name: Graptophyllum pictum Whole plant of Indonesian name (Daum wungu) Scientific name: Usnea spp. Whole plant of Indonesian name (Akar angin) Scientific name: Rheum officinale Indonesia Scientific name of Sindora javanica Indonesian name (Saparantu) Scientific name of Vitex trifolia Indonesian name (Legundi) Leaf Scientific name: Anacardium occidentale Indonesian name (Daun jambu mete) Leaf Scientific name: Gymnopetalum leucosticum Indonesian name (Duri kemarung) Scientific name: Equisetum debile Indonesian name (Greges otot) Stem Scientific name: Kyllinga monocephala Indonesian name (Ak Scientific name: Kyllinga brevifolia Scientific name: Indonesian name (Akar teki) Scientific name: Ardisia fuliginosa Scientific name: Indonesian name (Ajag) Scientific name: Entada phaseoloides Indonesian name (Tariyu) stem / leaf Scientific name: Alyxia reinwardti Indonesian name (Kayu polo sari) stalk selected from one or more Indonesian folklore as it is, or its extract as an active ingredient,
It may be formulated by combining this with a known pharmaceutical carrier.
【0019】本発明のNO産生抑制剤は、経口剤や、注
射剤、点滴用剤等の非経口剤のいずれによっても投与す
ることができる。The NO production inhibitor of the present invention can be administered as an oral agent or a parenteral agent such as an injection or an infusion.
【0020】医薬用担体は、上記投与形態および剤型に
応じて選択することができ、経口剤の場合は、例えばデ
ンプン、乳糖、白糖、マンニット、カルボキシメチルセ
ルロース、コーンスターチ、無機塩等が利用される。ま
た、経口剤の調製にあたっては、更に結合剤、崩壊剤、
界面活性剤、滑沢剤、流動性促進剤、矯味剤、着色剤、
香料等を配合することができる。これらの具体例として
は、以下に示すものが挙げられる。Pharmaceutical carriers can be selected according to the above-mentioned administration forms and dosage forms. In the case of oral preparations, for example, starch, lactose, sucrose, mannitol, carboxymethylcellulose, corn starch, inorganic salts and the like are used. You. In addition, in preparing an oral preparation, a binder, a disintegrant,
Surfactants, lubricants, fluidity promoters, flavoring agents, coloring agents,
Flavors and the like can be blended. Specific examples thereof include the following.
【0021】結合剤としては、例えばデンプン、デキス
トリン、アラビアゴム末、ゼラチン、ヒドロキシプロピ
ルスターチ、メチルセルロース、カルボキシメチルセル
ロースナトリウム、ヒドロキシプロピルセルロース、結
晶セルロース、エチルセルロース、ポリビニルピロリド
ン、マクロゴールなどが挙げられる。Examples of the binder include starch, dextrin, gum arabic, gelatin, hydroxypropyl starch, methylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, crystalline cellulose, ethylcellulose, polyvinylpyrrolidone, macrogol and the like.
【0022】崩壊剤としては、例えばデンプン、ヒドロ
キシプロピルスターチ、カルボキシメチルセルロースナ
トリウム、カルボキシメチルセルロースカルシウム、カ
ルボキシメチルセルロース、低置換ヒドロキシプロピル
セルロースなどが挙げられる。Examples of the disintegrant include starch, hydroxypropyl starch, sodium carboxymethylcellulose, calcium carboxymethylcellulose, carboxymethylcellulose, low-substituted hydroxypropylcellulose and the like.
【0023】界面活性剤としては、例えばラウリル硫酸
ナトリウム、大豆レシチン、ショ糖脂肪酸エステル、ポ
リソルベート80などが挙げられる。Examples of the surfactant include sodium lauryl sulfate, soybean lecithin, sucrose fatty acid ester, polysorbate 80 and the like.
【0024】滑沢剤としては、例えばタルク、ロウ類、
水素添加植物油、ショ糖脂肪酸エステル、ステアリン酸
マグネシウム、ステアリン酸カルシウム、ステアリン酸
アルミニウム、ポリエチレングリコールなどが挙げられ
る。As the lubricant, for example, talc, waxes,
Examples include hydrogenated vegetable oils, sucrose fatty acid esters, magnesium stearate, calcium stearate, aluminum stearate, polyethylene glycol and the like.
【0025】流動性促進剤としては、例えば軽質無水ケ
イ酸、乾燥水酸化アルミニウムゲル、合成ケイ酸アルミ
ニウム、ケイ酸マグネシウムなどが挙げられる。Examples of the fluidity promoter include light anhydrous silicic acid, dried aluminum hydroxide gel, synthetic aluminum silicate, magnesium silicate and the like.
【0026】また、本発明のNO産生抑制剤は、懸濁
液、エマルジョン剤、シロップ剤、エリキシル剤等の経
口用の液剤としても投与することができ、これらの各種
剤形には、矯味矯臭剤、着色剤を配合することができ
る。The NO production inhibitor of the present invention can also be administered as oral liquids such as suspensions, emulsions, syrups, elixirs and the like. Agents and coloring agents can be added.
【0027】一方、非経口剤の場合は、常法に従って製
造され、希釈剤として一般に注射用蒸留水、生理食塩
水、ブドウ糖水溶液、注射用植物油、ゴマ油、ラッカセ
イ油、ダイズ油、トウモロコシ油、プロピレングリコー
ル、ポリエチレングリコール等を用いることができる。
さらに必要に応じて、殺菌剤、防腐剤、安定剤を加えて
もよい。また、この非経口剤は安定性の点から、バイア
ル等に充填後冷凍し、通常の凍結乾燥技術により水分を
除去し、使用直前に凍結乾燥物から液剤を再調製するこ
ともできる。さらに、必要に応じて適宜、等張化剤、安
定剤、防腐剤、無痛化剤等を配合することもできる。On the other hand, parenteral preparations are prepared according to a conventional method, and are generally used as diluents: distilled water for injection, physiological saline, aqueous glucose solution, vegetable oil for injection, sesame oil, peanut oil, soybean oil, corn oil, propylene oil. Glycol, polyethylene glycol and the like can be used.
Further, if necessary, a bactericide, a preservative, and a stabilizer may be added. Further, from the viewpoint of stability, this parenteral preparation can be frozen after filling into a vial or the like, water can be removed by a usual freeze-drying technique, and a liquid preparation can be prepared from the freeze-dried product immediately before use. Further, if necessary, an isotonic agent, a stabilizer, a preservative, a soothing agent and the like can be appropriately added.
【0028】本発明のNO産生抑制剤の投与量は、投与
経路、疾患の程度、被投与者の年齢等によって異なる
が、一般には経口投与の場合、大人1 日当たり、上記植
物より選ばれる1 種または2 種以上の生薬の乾燥エキス
量として1 〜10g 程度となる量を1 〜3 回に分けて投与
すればよい。The dose of the NO production inhibitor of the present invention varies depending on the route of administration, the degree of the disease, the age of the recipient, and the like. In general, in the case of oral administration, one species selected from the above plants is used per adult per day. Alternatively, the amount of the dry extract of two or more crude drugs may be about 1 to 10 g in 1 to 3 divided doses.
【0029】なお、本発明で用いる各種生薬はジャムウ
の構成植物としてすでに長い歴史を有し、安全性が確認
されたものであるので、安心して使用することができ
る。例えば、マウスおよびラットに対し、投与限界であ
る15g/kgの経口投与で死亡例も異常所見も認められない
ことから明らかなように極めて安全性の高いものであ
る。The various crude drugs used in the present invention have a long history as a component plant of jamu and have been confirmed to be safe, so that they can be used with confidence. For example, oral administration of 15 g / kg, which is the administration limit, to mice and rats is extremely safe as apparent from the fact that no deaths or abnormal findings were observed.
【0030】本発明のNO産生抑制剤は、食品、飼料等
へ常法に従って添加することができ、その添加量は製品
の種類に応じて適宜選択することができるが、通常、製
品の全重量に対して0. 001〜5重量%が適当であ
り、さらに0. 005〜2重量%とすることが好まし
い。本発明のNO産生抑制剤の適用製品として、具体的
には、パスタ、チューインガム、チューイングゼリー、
コーヒー飲料等の食品、ドッグフード、キャットフード
等の飼料が挙げられる。The NO production inhibitor of the present invention can be added to foods, feeds and the like according to a conventional method, and the amount of addition can be appropriately selected according to the type of the product. Is 0.001 to 5% by weight, and more preferably 0.005 to 2% by weight. As a product to which the NO production inhibitor of the present invention is applied, specifically, pasta, chewing gum, chewing jelly,
Foods such as coffee drinks and feeds such as dog foods and cat foods are included.
【0031】[0031]
【実施例】次に製造例および実施例を挙げ本発明を更に
詳しく説明するが、本発明はこれら実施例に何ら制約さ
れるものではない。製造例1 学名:Andrographis paniculata インドネシア名(Sambi
boto)の全草乾燥物の破砕物100gに対して、50 v
/v%エタノール1,000mlを加え、室温暗所にて7
日間攪拌抽出を行った。これを遠心分離・加圧ろ過し、
抽出液を得た。この抽出液と凍結乾燥し抽出物を得た。製造例2 学名:Caesalpinia sappanインドネシア名(Kaya secan
g) の木部乾燥物の破砕物100gに対して、50 v/v
%エタノール1,000mlを加え、室温暗所にて7日
間攪拌抽出を行った。これを遠心分離・加圧ろ過し、抽
出液を得た。この抽出液と凍結乾燥し抽出物を得た。製造例3 学名:Schima wallichii インドネシア名(Buah cangko
k) 実乾燥物の破砕物100gに対して、50 v/v%エ
タノール1,000mlを加え、室温暗所にて7日間攪
拌抽出を行った。これを遠心分離・加圧ろ過し、抽出液
を得た。この抽出液と凍結乾燥し抽出物を得た。製造例4 学名:Alstonia scholaris インドネシア名(Babakan p
ule)の樹皮乾燥物の破砕物100gに対して、50 v/v
%エタノール1,000mlを加え、室温暗所にて7日
間攪拌抽出を行った。これを遠心分離・加圧ろ過し、抽
出液を得た。この抽出液と凍結乾燥し抽出物を得た。製造例5 学名:Graptophyllum pictum インドネシア名(Daum wu
ngu)の全草乾燥物の破砕物100gに対して、50 v/v
%エタノール1,000mlを加え、室温暗所にて7日
間攪拌抽出を行った。これを遠心分離・加圧ろ過し、抽
出液を得た。この抽出液と凍結乾燥し抽出物を得た。製造例6 学名:Usnea spp. インドネシア名(Akar angin)の全草
乾燥物の破砕物100gに対して、50 v/v%エタノー
ル1,000mlを加え、室温暗所にて7日間攪拌抽出
を行った。これを遠心分離・加圧ろ過し、抽出液を得
た。この抽出液と凍結乾燥し抽出物を得た。製造例7 学名:Rheum officinale インドネシア名(Klembak) の
根乾燥物の破砕物100gに対して、50 v/v%エタノ
ール1,000mlを加え、室温暗所にて7日間攪拌抽
出を行った。これを遠心分離・加圧ろ過し、抽出液を得
た。この抽出液と凍結乾燥し抽出物を得た。製造例8 学名: Sindora javanica インドネシア名(Saparantu)
の実乾燥物の破砕物100gに対して、50 v/v%エタ
ノール1,000mlを加え、室温暗所にて7日間攪拌
抽出を行った。これを遠心分離・加圧ろ過し、抽出液を
得た。この抽出液と凍結乾燥し抽出物を得た。製造例9 学名:Vitex trifolia インドネシア名(Legundi) の葉
乾燥物の破砕物100gに対して、50 v/v%エタノー
ル1,000mlを加え、室温暗所にて7日間攪拌抽出
を行った。これを遠心分離・加圧ろ過し、抽出液を得
た。この抽出液と凍結乾燥し抽出物を得た。製造例10 学名:Anacardium occidentale インドネシア名(Daun
jambu mete) の葉乾燥物の破砕物100gに対して、5
0 v/v%エタノール1,000mlを加え、室温暗所に
て7日間攪拌抽出を行った。これを遠心分離・加圧ろ過
し、抽出液を得た。この抽出液と凍結乾燥し抽出物を得
た。製造例11 学名: Gymnopetalum leucosticum インドネシア名(Dur
i kemarung) の棘乾燥物の破砕物100gに対して、5
0 v/v%エタノール1,000mlを加え、室温暗所に
て7日間攪拌抽出を行った。これを遠心分離・加圧ろ過
し、抽出液を得た。この抽出液と凍結乾燥し抽出物を得
た。製造例12 学名: Equisetum debile インドネシア名(Greges oto
t) の茎乾燥物の破砕物100gに対して、50 v/v%
エタノール1,000mlを加え、室温暗所にて7日間
攪拌抽出を行った。これを遠心分離・加圧ろ過し、抽出
液を得た。この抽出液と凍結乾燥し抽出物を得た。製造例13 学名: Kyllinga monocephala インドネシア名(Akar te
ki) の全草乾燥物の破砕物100gに対して、50 v/v
%エタノール1,000mlを加え、室温暗所にて7日
間攪拌抽出を行った。これを遠心分離・加圧ろ過し、抽
出液を得た。この抽出液と凍結乾燥し抽出物を得た。製造例14 学名: Kyllinga brevifolia インドネシア名(Akar te
ki) の全草乾燥物の破砕物100gに対して、50v/v
%エタノール1,000mlを加え、室温暗所にて7日
間攪拌抽出を行った。これを遠心分離・加圧ろ過し、抽
出液を得た。この抽出液と凍結乾燥し抽出物を得た。製造例15 学名:Ardisia fuliginosa インドネシア名(Ajag)の全
草乾燥物の破砕物100gに対して、50v/v %エタノ
ール1,000mlを加え、室温暗所にて7日間攪拌抽
出を行った。これを遠心分離・加圧ろ過し、抽出液を得
た。この抽出液と凍結乾燥し抽出物を得た。製造例16 学名: Entada phaseoloides インドネシア名(Tariyu)
の茎・葉乾燥物の破砕物100gに対して、50 v/v%
エタノール1,000mlを加え、室温暗所にて7日間
攪拌抽出を行った。これを遠心分離・加圧ろ過し、抽出
液を得た。この抽出液と凍結乾燥し抽出物を得た。製造例17 学名:Alyxia reinwardti インドネシア名(Kayu polo s
ari)の茎乾燥物の破砕物100gに対して、50 v/v%
エタノール1,000mlを加え、室温暗所にて7日間
攪拌抽出を行った。これを遠心分離・加圧ろ過し、抽出
液を得た。この抽出液と凍結乾燥し抽出物を得た。EXAMPLES Next, the present invention will be described in more detail with reference to Production Examples and Examples, but the present invention is not limited to these Examples. Production Example 1 Scientific name: Andrographis paniculata Indonesian name (Sambi
boto) 50 g for 100 g of crushed dried whole plant
/ v% ethanol (1,000 ml)
Stirring extraction was performed for a day. This is centrifuged and filtered under pressure,
An extract was obtained. This extract was freeze-dried to obtain an extract. Production Example 2 Scientific name: Caesalpinia sappan Indonesian name (Kaya secan
g) 50 v / v per 100 g of crushed dried xylem
1,000 ml of ethanol was added thereto, and the mixture was extracted with stirring at room temperature in a dark place for 7 days. This was centrifuged and filtered under pressure to obtain an extract. This extract was freeze-dried to obtain an extract. Production Example 3 Scientific name: Schima wallichii Indonesian name (Buah cangko
k) 1,000 g of 50 v / v% ethanol was added to 100 g of the actually dried crushed product, and the mixture was extracted with stirring at room temperature in a dark place for 7 days. This was centrifuged and filtered under pressure to obtain an extract. This extract was freeze-dried to obtain an extract. Production Example 4 Scientific name: Alstonia scholaris Indonesian name (Babakan p
ule), 50 v / v for 100 g of the crushed dry bark
1,000 ml of ethanol was added thereto, and the mixture was extracted with stirring at room temperature in a dark place for 7 days. This was centrifuged and filtered under pressure to obtain an extract. This extract was freeze-dried to obtain an extract. Production Example 5 Scientific name: Graphtophyllum pictum Indonesian name (Daum wu
ngu), 50 v / v for 100 g of crushed dried whole plant
1,000 ml of ethanol was added thereto, and the mixture was extracted with stirring at room temperature in a dark place for 7 days. This was centrifuged and filtered under pressure to obtain an extract. This extract was freeze-dried to obtain an extract. Production Example 6 Scientific name: Usnea spp. To 100 g of crushed dried whole plant of Indonesian name (Akar angin), 1,000 ml of 50 v / v% ethanol was added, and the mixture was stirred and extracted in a dark place at room temperature for 7 days. Was. This was centrifuged and filtered under pressure to obtain an extract. This extract was freeze-dried to obtain an extract. Production Example 7 Scientific name: Rheum officinale To 100 g of crushed dried roots of Indonesian name (Klembak), 1,000 ml of 50 v / v% ethanol was added, and the mixture was stirred and extracted in a dark place at room temperature for 7 days. This was centrifuged and filtered under pressure to obtain an extract. This extract was freeze-dried to obtain an extract. Production Example 8 Scientific name: Sindora javanica Indonesian name (Saparantu)
1,000 g of 50 v / v% ethanol was added to 100 g of the crushed product of the actual dried product, and the mixture was extracted with stirring at room temperature in a dark place for 7 days. This was centrifuged and filtered under pressure to obtain an extract. This extract was freeze-dried to obtain an extract. Production Example 9 Scientific name: Vitex trifolia To 100 g of crushed dried leaf of Indonesian name (Legundi), 1,000 ml of 50 v / v% ethanol was added, and the mixture was stirred and extracted at room temperature in a dark place for 7 days. This was centrifuged and filtered under pressure to obtain an extract. This extract was freeze-dried to obtain an extract. Production example 10 Scientific name: Anacardium occidentale Indonesian name (Daun
jambu mete)
1,000 ml of 0 v / v% ethanol was added, and the mixture was stirred and extracted in a dark place at room temperature for 7 days. This was centrifuged and filtered under pressure to obtain an extract. This extract was freeze-dried to obtain an extract. Production example 11 Scientific name: Gymnopetalum leucosticum Indonesian name (Dur
i kemarung) 5 g
1,000 ml of 0 v / v% ethanol was added, and the mixture was stirred and extracted in a dark place at room temperature for 7 days. This was centrifuged and filtered under pressure to obtain an extract. This extract was freeze-dried to obtain an extract. Production example 12 Scientific name: Equisetum debile Indonesian name (Greges oto
t) 50 v / v% to 100 g of crushed dried stem
1,000 ml of ethanol was added, and the mixture was stirred and extracted in a dark place at room temperature for 7 days. This was centrifuged and filtered under pressure to obtain an extract. This extract was freeze-dried to obtain an extract. Production example 13 Scientific name: Kyllinga monocephala Indonesian name (Akar te
ki) 50 v / v for 100 g of crushed dried whole plant
1,000 ml of ethanol was added thereto, and the mixture was extracted with stirring at room temperature in a dark place for 7 days. This was centrifuged and filtered under pressure to obtain an extract. This extract was freeze-dried to obtain an extract. Production example 14 Scientific name: Kyllinga brevifolia Indonesian name (Akar te
ki), 50 v / v for 100 g of crushed dried whole plant
1,000 ml of ethanol was added thereto, and the mixture was extracted with stirring at room temperature in a dark place for 7 days. This was centrifuged and filtered under pressure to obtain an extract. This extract was freeze-dried to obtain an extract. Production Example 15 Scientific name: Ardisia fuliginosa To 100 g of a crushed dried whole plant under the name of Indonesia (Ajag), 1,000 ml of 50 v / v% ethanol was added, and the mixture was extracted with stirring at room temperature in a dark place for 7 days. This was centrifuged and filtered under pressure to obtain an extract. This extract was freeze-dried to obtain an extract. Production example 16 Scientific name: Entada phaseoloides Indonesian name (Tariyu)
50 v / v% for 100 g of crushed dried stem and leaf
1,000 ml of ethanol was added, and the mixture was stirred and extracted in a dark place at room temperature for 7 days. This was centrifuged and filtered under pressure to obtain an extract. This extract was freeze-dried to obtain an extract. Production Example 17 Scientific name: Alyxia reinwardti Indonesian name (Kayu polo s
ari) 50 v / v% to 100 g of crushed dried stem
1,000 ml of ethanol was added, and the mixture was stirred and extracted in a dark place at room temperature for 7 days. This was centrifuged and filtered under pressure to obtain an extract. This extract was freeze-dried to obtain an extract.
【0032】実施例1マクロファージが産生するNO量のin vitro測定 マクロファージを誘導することが知られているBCG (弱
毒結核菌)1μg/mouse を腹腔内投与し、4日後に
誘導腹腔マクロファージを採取した。これを96ウェルプ
レートにまき、2時間インキュベートしてマクロファー
ジをプレートに付着させ、上清を取り除いた。製造例で
得た各植物抽出物を50μg/mlとマクロファージを刺激
してNOを産生させるエンドトキシンであるリポポリサ
ッカライド(LPS)10μg /m1の両者を加えて2
4時間インキュベートした後、培養上清中に産生放出さ
れたNOをGriess試薬を用いて呈色させ、吸光度を測定す
ることによって定量した。Example 1 In Vitro Measurement of the Amount of NO Produced by Macrophages 1 μg / mouse of BCG (attenuated Mycobacterium tuberculosis) known to induce macrophages was intraperitoneally administered, and 4 days later, the induced peritoneal macrophages were collected. . This was spread on a 96-well plate, incubated for 2 hours to allow macrophages to adhere to the plate, and the supernatant was removed. Each of the plant extracts obtained in the Production Examples was added to both 50 μg / ml and 10 μg / ml of lipopolysaccharide (LPS), which is an endotoxin that stimulates macrophages to produce NO.
After incubation for 4 hours, NO produced and released in the culture supernatant was colored using Griess reagent and quantified by measuring absorbance.
【0033】上記実験を2回に分けて行った。結果を表
1および表2に示す。The above experiment was performed in two parts. The results are shown in Tables 1 and 2.
【0034】[0034]
【表1】 [Table 1]
【0035】[0035]
【表2】 [Table 2]
【0036】表1および表2に示すように、 学名: Andrographis paniculata インドネシア名(Sambi boto) 学名: Caesalpinia sappan インドネシア名(Kaya secang) 学名: Schima wallichii インドネシア名(Buah cangkok) 学名: Alstonia scholaris インドネシア名(Babakan pule) 学名: Graptophyllum pictum インドネシア名(Daum wungu) 学名: Usnea spp. インドネシア名(Akar angin) 学名: Rheum officinale インドネシア名(Klembak) 学名: Sindora javanica インドネシア名(Saparantu) 学名: Vitex trifolia インドネシア名(Legundi) 学名: Anacardium occidentale インドネシア名(Daun jambu mete) 学名: Gymnopetalum leucosticum インドネシア名(Duri kemarung) 学名: Equisetum debile インドネシア名(Greges otot) 学名: Kyllinga monocephala インドネシア名(Akar teki) 学名: Kyllinga brevifolia インドネシア名(Akar teki) 学名: Ardisia fuliginosa インドネシア名(Ajag) 学名: Entada phaseoloides インドネシア名(Tariyu) の抽出物にマクロファージ細胞に対して強いNO産生抑
制作用を認めた。したがって、本発明により明らかにさ
れた植物およびその抽出液は、BCGにより強く活性を
受け、エンドトキシン(LPS)によって刺激されたマ
クロファージから産生されるNOを抑制することが示さ
れた。As shown in Table 1 and Table 2, scientific name: Andrographis paniculata Indonesian name (Sambi boto) Scientific name: Caesalpinia sappan Indonesian name (Kaya secang) Scientific name: Schima wallichii Indonesian name (Buah cangkok) Scientific name: Alstonia scholaris Indonesian name ( Babakan pule) Scientific name: Graptophyllum pictum Indonesian name (Daum wungu) Scientific name: Usnea spp. Indonesian name (Akar angin) Scientific name: Rheum officinale Indonesian name (Klembak) Scientific name: Sindora javanica Indonesian name (Saparantu) Scientific name: Vitex trifolia Indonesian name Scientific name: Anacardium occidentale Indonesian name (Daun jambu mete) Scientific name: Gymnopetalum leucosticum Indonesian name (Duri kemarung) Scientific name: Equisetum debile Indonesian name (Greges otot) Scientific name: Kyllinga monocephala Indonesian name (Akar teki) teki) Scientific name: Ardisia fuliginosa Indonesian name (A jag) Scientific name: Entada phaseoloides An extract of Indonesian name (Tariyu) showed a strong NO production inhibitory effect on macrophage cells. Therefore, it was shown that the plant and the extract thereof revealed by the present invention were strongly activated by BCG and suppressed NO produced from macrophages stimulated by endotoxin (LPS).
【0037】実施例2マクロファージが産生するNO量のin vivo 測定 BCG誘導マウス腹腔内マクロファージが産生するNO
量を、Kondo.Y.,Takano,F.,Hojo H.,Biochem.Pharmaco
l.,46,1887-1892,1993 に記載された方法に準じて以下
のように行った。ICR マウス♂5週令を5日訓化後、各
群3匹ずつ用いた。製造例で得た各植物抽出物を水に溶
解、懸濁後、50mg/kg/day のdoseで1日1回経口投与し
た。3日目の投与後、マクロファージを誘導することが
知られているBCG(弱毒結核菌)1μg/mouse を
腹腔内投与し、4日後に誘導腹腔マクロファージを採取
した。これを24ウェルプレートにまき、2時間インキュ
ベートしてマクロファージをプレートに付着させ、上清
を取り除いた。マクロファージを刺激してNOを産生さ
せるエンドトキシンであるリポポリサッカライド(LP
S)10μg /m1を加えて24時間インキュベートし
た後、培養上清中に産生放出されたNOをGriess試薬を
用いて呈色させ、吸光度を測定することによって定量し
た。Example 2 In Vivo Measurement of the Amount of NO Produced by Macrophages NO Produced by BCG-Induced Mouse Intraperitoneal Macrophages
The amount was determined by Kondo.Y., Takano, F., Hojo H., Biochem.Pharmaco.
l, 46, 1887-1892, 1993, according to the method described below. After 5 days of ICR mouse ♂5-week-old training, 3 mice were used in each group. Each plant extract obtained in Production Example was dissolved and suspended in water, and orally administered once daily at a dose of 50 mg / kg / day. After the administration on the third day, 1 μg / mouse of BCG (attenuated Mycobacterium tuberculosis) known to induce macrophages was intraperitoneally administered, and four days later, the induced peritoneal macrophages were collected. This was spread on a 24-well plate, incubated for 2 hours to allow macrophages to adhere to the plate, and the supernatant was removed. Lipopolysaccharide (LP), an endotoxin that stimulates macrophages to produce NO
S) After adding 10 μg / ml and incubating for 24 hours, NO produced and released in the culture supernatant was colored using Griess reagent and quantified by measuring absorbance.
【0038】上記実験の結果を表3に示す。Table 3 shows the results of the above experiment.
【表3】 [Table 3]
【0039】表3に示すとおり 学名: Andrographis paniculata インドネシア名(Sambi boto) 学名: Alstonia scholaris インドネシア名(Babakan pule) 学名: Alyxia reinwardti インドネシア名(Kayu polo sari) の抽出物にマクロファージ細胞に対して強いNO産生抑
制作用を認めた。したがって、本発明により明らかにさ
れた植物およびその抽出液は、BCGにより強く活性を
受け、エンドトキシン(LPS)によって刺激されたマ
クロファージから産生されるNOを抑制することが示さ
れた。As shown in Table 3, Scientific name: Andrographis paniculata Indonesian name (Sambi boto) Scientific name: Alstonia scholaris Indonesian name (Babakan pule) Scientific name: Alyxia reinwardti Extract of Indonesian name (Kayu polo sari) which is strong against macrophage cells A production inhibitory effect was observed. Therefore, it was shown that the plant and the extract thereof revealed by the present invention were strongly activated by BCG and suppressed NO produced from macrophages stimulated by endotoxin (LPS).
【0040】上記実験例1および実験例2の結果から本
発明の有効成分がNO産生抑制作用を有することが証明
された。From the results of Experimental Examples 1 and 2, it was proved that the active ingredient of the present invention had an NO production inhibiting effect.
【0041】応用例1 顆粒剤の調製: 製造例1により調製した抽出物の粉末2
00gを乳糖89gおよびステアリン酸マグネシウム1
gと混合し、この混合物を単発式打錠機にて打錠し、直
径20mm、重量約2.3gのスラッグ錠を得た。このス
ラッグ錠をオシレーターで粉砕し、整粒後篩別し、粒径
20〜50メッシュの顆粒剤を得た。 Application Example 1 Preparation of granules: Extract powder 2 prepared according to Production Example 1
00 g to 89 g of lactose and magnesium stearate 1
g, and the mixture was tableted with a single-shot tableting machine to obtain a slug tablet having a diameter of 20 mm and a weight of about 2.3 g. The slug tablet was pulverized with an oscillator, sized and sieved to obtain granules having a particle size of 20 to 50 mesh.
【0042】応用例2 錠剤の調製: 製造例2で調製した抽出物200mgを微結
晶セルロース20およびステアリン酸マグネシウム5g
と混合し、この混合物を単発式打錠機にて打錠して直径
7mm、重量225mgの錠剤を製造した。本錠剤1錠中に
は、虎杖根の乾燥エキス粉末を200mg含有する。 Application Example 2 Preparation of tablet: 200 mg of the extract prepared in Production Example 2 was microcrystalline cellulose 20 and magnesium stearate 5 g
And a tablet having a diameter of 7 mm and a weight of 225 mg was produced by tableting with a single-shot tableting machine. One tablet of the present invention contains 200 mg of dried extract powder of Tiger root.
【0043】応用例3 カプセル剤の調製: 製造例3で調製した抽出物500mg
を硬カプセルに充填し、カプセル剤を調製した。 Application Example 3 Preparation of capsule: 500 mg of the extract prepared in Production Example 3
Was filled in a hard capsule to prepare a capsule.
【0044】応用例4 コーヒー飲料の製造:常法に従い、下記表4の配合によ
り製造した。 Application Example 4 Production of Coffee Beverage: Produced according to a conventional method according to the formulation shown in Table 4 below.
【0045】[0045]
【表4】 ──────────────────────────────── 成 分 分量(%) ──────────────────────────────── インスタントコーヒー 1. 7 グラニュー糖 5. 0 製造例4 で得た抽出物 0. 05 水(又は湯) 適量 ──────────────────────────────── 合計 100. 0 ────────────────────────────────[Table 4] ──────────────────────────────── Component Content (%) ────────イ ン ス タ ン ト Instant coffee 1.7 Granulated sugar 5.0 Extract obtained in Production Example 4 0.05 Water (or hot water) Suitable amount ──────────────────────────────── Total 100.0 ───────────── ───────────────────
【0046】応用例5 チューインガムの製造:常法に従い、下記表5の配合に
より製造した。 Application Example 5 Production of chewing gum: The chewing gum was produced according to a conventional method according to the formulation shown in Table 5 below.
【0047】[0047]
【表5】 ──────────────────────────────── 成 分 分量(%) ──────────────────────────────── ガムベース 31. 6 グラニュー糖 62. 5 グリセリン 0. 8 クエン酸 1. 0 ショ糖パルミテート 1. 0 リン酸3カルシウム 2. 0 製造例5 で得たエタノール抽出物 0. 1 香料 1. 0 ──────────────────────────────── 合計 100. 0 ────────────────────────────────[Table 5] ──────────────────────────────── Component Content (%) ──────── ──────────────────────── Gum base 31.6 Granulated sugar 62.5 Glycerin 0.8 Citric acid 1.0 Sucrose palmitate 1.0 Phosphoric acid Tricalcium 2.0 Ethanol extract obtained in Production Example 5 0.1 Fragrance 1.0 ─────────────────────────────合計 Total 100.0 ────────────────────────────────
【0048】応用例6 ドッグフードの製造:常法に従い、下記表6の配合によ
り製造した。 Application Example 6 Manufacture of dog food: Manufactured according to a conventional method according to the formulation shown in Table 6 below.
【0049】[0049]
【表6】 ──────────────────────────────── 成 分 分量(%) ──────────────────────────────── 小麦粉 30. 0 コーンフラワー 15. 0 大豆粉 15. 0 ミートミール 20. 0 砂糖 5. 0 牛脂 5. 0 食塩 1. 0 リン酸カルシウム 1. 5 ソルビン酸カリウム 0. 3 香料 0. 6 プロピレングリコール 6. 5 ──────────────────────────────── 合計 100. 0 ────────────────────────────────[Table 6] ──────────────────────────────── Component amount (%) ──────── Flour 30.0 Cornflower 15.0 Soybean flour 15.0 Meatmeal 20.0 Sugar 5.0 Tallow fat 5. 0 Salt 1.0 Calcium phosphate 1.5 Potassium sorbate 0.3 Flavor 0.6 Propylene glycol 6.5 ──────────────────────────合計 Total 100.0 ────────────────────────────────
【0050】上記配合物100重量部に対し水40重量
部を加え150℃、スクリュー圧縮比1:3でエクスト
ルダーにより押し出し成形した。40 parts by weight of water was added to 100 parts by weight of the above compound, and the mixture was extruded with an extruder at 150 ° C. and a screw compression ratio of 1: 3.
【0051】[0051]
【発明の効果】人体及び動物に対し有害な作用を示さ
ず、きわめて安全性が高い。食品及び飼料等へ配合する
ことにより、マクロファージの一酸化窒素産生を効果的
に抑制し、ショック、低血圧、慢性関節リウマチ、潰瘍
性大腸炎、虚血性脳障害、腫瘍、インスリン依存性糖尿
病等の治療および/又は予防に有用である。The present invention has no harmful effects on humans and animals and is extremely safe. Effectively suppresses macrophage nitric oxide production by blending it into foods and feeds, and reduces shock, hypotension, rheumatoid arthritis, ulcerative colitis, ischemic encephalopathy, tumors, insulin-dependent diabetes, etc. Useful for treatment and / or prevention.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61K 35/78 ADU A61K 35/78 ADU (72)発明者 曽田 良 大阪府大阪市中央区北浜4丁目7番28号 住友林業株式会社内 (72)発明者 伏谷 眞二 宮城県仙台市青葉区五橋2−8−7−601 (72)発明者 高野 文英 宮城県仙台市太白区長町8−2−31−104 Fターム(参考) 4C088 AA11 AA18 AB12 AB19 AB21 AB31 AB43 AB45 AB59 AB79 AC01 AC04 AC05 AC06 AC07 AC11 BA06 BA08 BA09 BA10 CA10 MA07 NA14 ZA15 ZA36 ZA43 ZA66 ZA68 ZB08 ZB11 ZB15 ZB26 ZC20 ZC35 ZC41──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) A61K 35/78 ADU A61K 35/78 ADU (72) Inventor Ryo Soda 4-7 Kitahama, Chuo-ku, Osaka-shi, Osaka No. 28 Sumitomo Forestry Co., Ltd. (72) Inventor Shinji Fushiya 2-8-7-601, Gobashi, Aoba-ku, Sendai City, Miyagi Prefecture (72) Inventor Fumihide Takano 8-2-231, Nagamachi, Taihaku-ku, Sendai City, Miyagi Prefecture 104 F term (reference) 4C088 AA11 AA18 AB12 AB19 AB21 AB31 AB43 AB45 AB59 AB79 AC01 AC04 AC05 AC06 AC07 AC11 BA06 BA08 BA09 BA10 CA10 MA07 NA14 ZA15 ZA36 ZA43 ZA66 ZA68 ZB08 ZB11 ZB15 ZB26 ZC20 ZC35 ZC41
Claims (3)
のもの、又は植物の溶媒抽出液あるいは炭酸ガスを使用
する超臨界抽出法により抽出された抽出物を有効成分と
して含有することを特徴とする一酸化窒素産生抑制剤。[Claim 1] Scientific name: Andrographis paniculata Indonesian name (Sambi boto) Scientific name: Caesalpinia sappan Indonesian name (Kaya secang) Scientific name: Schima wallichii Indonesian name (Buah cangkok) Scientific name: Alstonia scholaris Indonesian name (Babakan pule) Indonesian name: Graptoph Name (Daum wungu) Scientific name: Usnea spp. Indonesian name (Akar angin) Scientific name: Rheum officinale Indonesian name (Klembak) Scientific name: Sindora javanica Indonesian name (Saparantu) Scientific name: Vitex trifolia Indonesian name (Legundi) Scientific name: Anacardium occidentale Indonesian name Daun jambu mete) Scientific name: Gymnopetalum leucosticum Indonesian name (Duri kemarung) Scientific name: Equisetum debile Indonesian name (Greges otot) Scientific name: Kyllinga monocephala Indonesian name (Akar teki) Scientific name: Kyllinga brevifolia Indonesian name (Akar teki sci) (Ajag) Scientific name: Entada phaseoloides Inn At least one plant selected from the group consisting of the Nesia name (Tariyu) and the scientific name: Alyxia reinwardti Indonesian name (Kayu polo sari), or extracted by a supercritical extraction method using a solvent extract of plants or carbon dioxide gas A nitric oxide production inhibitor comprising the extracted extract as an active ingredient.
Kyllinga brevifolia インドネシア名(Akar teki) の全草 学名: Ardisia fuliginosa インドネシア名(Ajag)の全草 学名: Entada phaseoloides インドネシア名(Tariyu) の茎・葉 及び 学名: Alyxia reinwardti インドネシア名(Kayu polo sari)の茎 からなる群より選ばれる少なくとも一種以上の植物体そ
のもの、又は植物の溶媒抽出液あるいは炭酸ガスを使用
する超臨界抽出法により抽出された抽出物を有効成分と
して含有することを特徴とする一酸化窒素産生抑制剤。[Claim 2] Scientific name: Whole plant of Andrographis paniculata Indonesian name (Sambi boto) Scientific name: Caesalpinia sappan Indonesian name (Kaya secang) Kibe Scientific name: Schima wallichii Indonesian name (Buah cangkok) Real scientific name: Alstonia scholaris Indonesian name (Babakan) pule) bark Scientific name: Graptophyllum pictum Indonesian name (Daum wungu) whole plant Scientific name: Usnea spp. Indonesian name (Akar angin) whole plant Scientific name: Rheum officinale Indonesian name (Klembak) Root Scientific name: Sindora javanica Indonesian name (Saparantu) Scientific name: Vitex trifolia Indonesian name (Legundi) Leaf Scientific name: Anacardium occidentale Indonesian name (Daun jambu mete) Leaf Scientific name: Gymnopetalum leucosticum Indonesian name (Duri kemarung) Thorn Scientific name: Equisetum debile Indonesian name (Greges otot) Stem Scientific name: Kyllinga monocephala Indonesian name (Akar teki) Whole plant scientific name:
Kyllinga brevifolia Indonesian name (Akar teki) whole plant Scientific name: Ardisia fuliginosa Indonesian name (Ajag) whole plant Scientific name: Entada phaseoloides Indonesian name (Tariyu) stem and leaves and Scientific name: Alyxia reinwardti Indonesian name (Kayu polo sari) stem At least one plant selected from the group consisting of or a solvent extract of a plant or an extract extracted by a supercritical extraction method using carbon dioxide as an active ingredient. Production inhibitors.
エタノール、プロピレングリコール及び1, 3−ブチレ
ングリコールからなる群から選ばれる少なくとも1種で
あることを特徴とする請求項1又は2記載の一酸化窒素
産生抑制剤。3. The solvent is water, chloroform, methanol,
The nitric oxide production inhibitor according to claim 1 or 2, wherein the agent is at least one member selected from the group consisting of ethanol, propylene glycol and 1,3-butylene glycol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10200543A JP2000034233A (en) | 1998-07-15 | 1998-07-15 | Inhibitor of production of nitric oxide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10200543A JP2000034233A (en) | 1998-07-15 | 1998-07-15 | Inhibitor of production of nitric oxide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2000034233A true JP2000034233A (en) | 2000-02-02 |
Family
ID=16426063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10200543A Pending JP2000034233A (en) | 1998-07-15 | 1998-07-15 | Inhibitor of production of nitric oxide |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2000034233A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7341748B2 (en) | 2004-04-28 | 2008-03-11 | Hutchison Medipharma Enterprises Limited | Crude extracts from Andrographis paniculata |
| WO2008084283A3 (en) * | 2006-07-07 | 2008-11-27 | Avestha Gengraine Tech Pvt Ltd | Andrographis paniculata plant extracts for treating osteoporosis and the extraction process thereof |
| JP2009232793A (en) | 2008-03-27 | 2009-10-15 | Genichiro Soma | Feed additive, feed, method for producing the feed additive and the feed, death-preventive agent, and breeding method |
| JP2013209299A (en) * | 2012-03-30 | 2013-10-10 | Kose Corp | Dna damage suppressant, and skin care preparation, cosmetic material and food and drink containing the same |
| US8557308B2 (en) | 2007-11-02 | 2013-10-15 | Nutrition Science Partners Limited | Andrographis paniculata extract |
| WO2013183523A1 (en) * | 2012-06-08 | 2013-12-12 | 花王株式会社 | Method for producing extract from lichen belonging to genus usnea |
| JP2013253058A (en) * | 2012-06-08 | 2013-12-19 | Kao Corp | Process for producing extract from lichen belonging to genus usnea |
| JP2013253059A (en) * | 2012-06-08 | 2013-12-19 | Kao Corp | Process for producing extract from lichen belonging to genus usnea |
-
1998
- 1998-07-15 JP JP10200543A patent/JP2000034233A/en active Pending
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7341748B2 (en) | 2004-04-28 | 2008-03-11 | Hutchison Medipharma Enterprises Limited | Crude extracts from Andrographis paniculata |
| AU2005237550B2 (en) * | 2004-04-28 | 2010-09-23 | Nutrition Science Partners Limited | Crude extracts from andrographis paniculata |
| USRE42718E1 (en) | 2004-04-28 | 2011-09-20 | Hutchison Medipharma Enterprises Limited | Crude extracts from andrographis paniculata |
| USRE43423E1 (en) | 2004-04-28 | 2012-05-29 | Hutchison Medipharma Enterprises Limited | Crude extracts from Andrographis paniculata |
| WO2008084283A3 (en) * | 2006-07-07 | 2008-11-27 | Avestha Gengraine Tech Pvt Ltd | Andrographis paniculata plant extracts for treating osteoporosis and the extraction process thereof |
| US8557308B2 (en) | 2007-11-02 | 2013-10-15 | Nutrition Science Partners Limited | Andrographis paniculata extract |
| US8557302B2 (en) | 2007-11-02 | 2013-10-15 | Nutrition Science Partners Limited | Andrographis paniculata extract |
| JP2009232793A (en) | 2008-03-27 | 2009-10-15 | Genichiro Soma | Feed additive, feed, method for producing the feed additive and the feed, death-preventive agent, and breeding method |
| JP2013209299A (en) * | 2012-03-30 | 2013-10-10 | Kose Corp | Dna damage suppressant, and skin care preparation, cosmetic material and food and drink containing the same |
| WO2013183523A1 (en) * | 2012-06-08 | 2013-12-12 | 花王株式会社 | Method for producing extract from lichen belonging to genus usnea |
| JP2013253058A (en) * | 2012-06-08 | 2013-12-19 | Kao Corp | Process for producing extract from lichen belonging to genus usnea |
| JP2013253059A (en) * | 2012-06-08 | 2013-12-19 | Kao Corp | Process for producing extract from lichen belonging to genus usnea |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002524480A (en) | Bioflavonoids as hypoglycemic agents | |
| JP2008526834A (en) | Use of lignan compounds for the treatment or prevention of inflammatory diseases | |
| JP2009536640A (en) | Composition comprising at least one higher fatty alcohol and an extract of glyphonia simplicifolia | |
| WO2004091645A2 (en) | Composition comprising rosmarinic acid, borneol and ginsenoside | |
| US11147850B2 (en) | Synergistic composition for osteoarthritis | |
| JP3768795B2 (en) | Xanthine oxidase inhibitor | |
| BR112015005942B1 (en) | composition comprising extracts of cynara, coffea spp. and olea europaea, its use and pharmaceutical composition | |
| JP2000034233A (en) | Inhibitor of production of nitric oxide | |
| JP2003527418A (en) | Use of cocoa procyanidin in combination with acetylsalicylic acid as antiplatelet therapy | |
| JPH07324039A (en) | Nitric oxide production promoter | |
| JPWO2018151334A1 (en) | Xanthine oxidase inhibitor and method for producing the same | |
| JP2022096826A (en) | Oral composition | |
| EA010910B1 (en) | TREATMENT OF STABILITY TO ASPIRIN USING RADIX SALVIAE MILTIORRHIZAE, HIS EXTRACT AND COMPOSITION | |
| KR101916909B1 (en) | composition for improvement of vascular endothelial dysfunction | |
| Andalib et al. | Comparison of hepatoprotective activity of Cichorium intybus and Cynara scolymus extracts against paracetamol induced hepatotoxicity in broiler chicken | |
| KR20170033101A (en) | Composition for improving liver function comprising citrulline as an active ingredient | |
| KR101332824B1 (en) | Pharmaceutical Compositions for Preventing or Treating Arthritis Comprising Euphorbia ebracteolata Extracts | |
| KR102191165B1 (en) | Anti-inflammatory composition using an extract of radish root, etc. | |
| CN1767844A (en) | Rosmarinic acid composition | |
| JP2006036787A (en) | Xanthine oxidase inhibitor | |
| JPS63295512A (en) | Carcinostatic agent | |
| KR102092729B1 (en) | Pharmaceutical composition for preventing or treating liver damage comprising Curcuma longa extract | |
| JP5969308B2 (en) | Nitric oxide secretion promoter or secretion inducer of vascular endothelial cells | |
| JP2019502743A (en) | Detoxifying composition for oral administration and method for its preparation | |
| MXPA05002081A (en) | Psidium guajava improved extracts, methods for obtaining and using the same in the treatment of gastrointestinal diseases. |